• Je něco špatně v tomto záznamu ?

Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma

R. Rais, A. Jančařík, L. Tenora, M. Nedelcovych, J. Alt, J. Englert, C. Rojas, A. Le, A. Elgogary, J. Tan, L. Monincová, K. Pate, R. Adams, D. Ferraris, J. Powell, P. Majer, BS. Slusher,

. 2016 ; 59 (18) : 8621-33. [pub] 20160906

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19013193

The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON, 1) has shown robust anticancer efficacy in preclinical and clinical studies, but its development was halted due to marked systemic toxicities. Herein we demonstrate that DON inhibits glutamine metabolism and provides antitumor efficacy in a murine model of glioblastoma, although toxicity was observed. To enhance DON's therapeutic index, we utilized a prodrug strategy to increase its brain delivery and limit systemic exposure. Unexpectedly, simple alkyl ester-based prodrugs were ineffective due to chemical instability cyclizing to form a unique diazo-imine. However, masking both DON's amine and carboxylate functionalities imparted sufficient chemical stability for biological testing. While these dual moiety prodrugs exhibited rapid metabolism in mouse plasma, several provided excellent stability in monkey and human plasma. The most stable compound (5c, methyl-POM-DON-isopropyl-ester) was evaluated in monkeys, where it achieved 10-fold enhanced cerebrospinal fluid to plasma ratio versus DON. This strategy may provide a path to DON utilization in glioblastoma multiforme patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013193
003      
CZ-PrNML
005      
20190415130041.0
007      
ta
008      
190405s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.6b01069 $2 doi
035    __
$a (PubMed)27560860
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rais, Rana
245    10
$a Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma / $c R. Rais, A. Jančařík, L. Tenora, M. Nedelcovych, J. Alt, J. Englert, C. Rojas, A. Le, A. Elgogary, J. Tan, L. Monincová, K. Pate, R. Adams, D. Ferraris, J. Powell, P. Majer, BS. Slusher,
520    9_
$a The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON, 1) has shown robust anticancer efficacy in preclinical and clinical studies, but its development was halted due to marked systemic toxicities. Herein we demonstrate that DON inhibits glutamine metabolism and provides antitumor efficacy in a murine model of glioblastoma, although toxicity was observed. To enhance DON's therapeutic index, we utilized a prodrug strategy to increase its brain delivery and limit systemic exposure. Unexpectedly, simple alkyl ester-based prodrugs were ineffective due to chemical instability cyclizing to form a unique diazo-imine. However, masking both DON's amine and carboxylate functionalities imparted sufficient chemical stability for biological testing. While these dual moiety prodrugs exhibited rapid metabolism in mouse plasma, several provided excellent stability in monkey and human plasma. The most stable compound (5c, methyl-POM-DON-isopropyl-ester) was evaluated in monkeys, where it achieved 10-fold enhanced cerebrospinal fluid to plasma ratio versus DON. This strategy may provide a path to DON utilization in glioblastoma multiforme patients.
650    _2
$a zvířata $7 D000818
650    _2
$a antimetabolity antitumorózní $x mok mozkomíšní $x terapeutické užití $7 D000964
650    _2
$a nádory mozku $x farmakoterapie $x metabolismus $7 D001932
650    _2
$a diazooxonorleucin $x mok mozkomíšní $x terapeutické užití $7 D003980
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glioblastom $x farmakoterapie $x metabolismus $7 D005909
650    _2
$a glutamin $x metabolismus $7 D005973
650    _2
$a Haplorrhini $7 D000882
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši nahé $7 D008819
650    _2
$a prekurzory léčiv $x farmakokinetika $x terapeutické užití $7 D011355
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jančařík, Andrej $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i. , Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
700    1_
$a Tenora, Lukáš $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i. , Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
700    1_
$a Nedelcovych, Michael
700    1_
$a Alt, Jesse
700    1_
$a Englert, Judson
700    1_
$a Rojas, Camilo
700    1_
$a Le, Anne
700    1_
$a Elgogary, Amira
700    1_
$a Tan, Jessica
700    1_
$a Monincová, Lenka $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i. , Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
700    1_
$a Pate, Kelly
700    1_
$a Adams, Robert
700    1_
$a Ferraris, Dana $u Department of Chemistry, McDaniel College , Westminster, Maryland 21157, United States.
700    1_
$a Powell, Jonathan
700    1_
$a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i. , Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
700    1_
$a Slusher, Barbara S
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 59, č. 18 (2016), s. 8621-33
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27560860 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190415130103 $b ABA008
999    __
$a ok $b bmc $g 1392503 $s 1051498
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 59 $c 18 $d 8621-33 $e 20160906 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20190405
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace